Dragonfly Therapeutics Competitors, Revenue and Alternatives

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:N/A
Industry:Biotech
Founded:2015
Lead Investor(s):Celgene

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Dragonfly Therapeutics's estimated annual revenue is currently $13.2M per year.
  • Dragonfly Therapeutics received $Undisclosed in venture funding in May 2017.
  • Dragonfly Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Dragonfly Therapeutics has 85 Employees.
  • Dragonfly Therapeutics grew their employee count by 49% last year.
  • Dragonfly Therapeutics currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ultivue
$8.7M56-12%N/AN/A
Ohana Bioscienc...
$8.7M5660%N/AN/A
Compass Therape...
$16.4M10614%N/AN/A
Cell Signaling ...
$89.4M577N/AN/AN/A
Momenta Pharmac...
N/A220N/AN/AN/A
Emulate
$15.3M99-17%N/AN/A
ArQule
N/A94N/AN/AN/A
Hamilton Storag...
$17.2M1119%N/AN/A
Alnylam Pharmac...
$74.9M127731%N/AN/A
Transgenomic
N/A47N/AN/AN/A
Missing a competitor? Contribute!?
Submit

Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer. We are developing novel first-in-class therapeutics targeted at natural killer cells and other cells of the innate immune system. These therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses. Our molecules are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies. Our scientific founders are major figures in cancer biology and immunology and have launched Dragonfly to harness the power of the immune system to provide breakthrough cancer treatments for patients. For more information, email info@dragonflytx.com.

keywords:N/A

85

Number of Employees

$13.2M

Revenue (est)

1

Current Jobs

49%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Executive Contacts

NameTitleEmail
Steve O'NeilPrincipal ScientistEmail Available
Michael ShifrinAssociate DirectorEmail Available
Stacey DrabicDirector of BiologyEmail Available
Hemanta BaruahAssociate Director Of Protein EngineeringEmail Available
Patrick KirbySenior Director, ToxicologyEmail Available
Sean JuoDirector, Protein EngineeringEmail Available
Sean RossiAssociate DirectorEmail Available
Anita ScheuberVice President Of Clinical Research
Lynn MarkowitzAssociate Director, Bioanalytical Sciences And Preclinical DevelopmentEmail Available
Marianna RowlandsDirector of Biology, Immuno-Oncology

Dragonfly Therapeutics News

09/07/2019 - RNA Expert Dr. Phillip Sharp Joins as Advisor to Skyhawk Therapeutics

4, 2019 /PRNewswire/ -- Skyhawk Therapeutics, Inc. ("Skyhawk"), today ... said Bill Haney, co-founder and CEO of Dragonfly Therapeutics.

09/08/2019 - Dragonfly Therapeutics Adds World-Leading Cancer ...

Dr. Alan Korman, renowned for his work leading to the development the first approved checkpoint inhibitor cancer therapies, joins Dragonfly's ...

10/01/2018 - Dragonfly Therapeutics in $695M cancer R&D pact with Merck

More than a year after insect-inspired biotech Dragonfly Therapeutics penned a blood cancer pact with big biotech Celgene, it's back at the ...

Dragonfly Therapeutics Funding

DateAmountRoundLead InvestorsReference
2017-05-18$UndisclosedUndisclosedCelgeneArticle

Dragonfly Therapeutics Executive Hires

DateNameTitleReference
2017-05-17Ann CheungHead Of BiologyArticle
2017-06-27Nicolai WagtmannCSOArticle
2018-01-30Jean Marie CuillerotChief Medical OfficerArticle